Inhibitors of mTOR alone or combined with other therapies did not achieve significant success in DLBCL clinical trials despite strong preclinical promise but were not tested in specific mutant contexts [36–38]. This evidence concerns the gene MTOR and diffuse large B-cell lymphoma.